한국어
Quantus

iNtRON Biotechnology

048530 · KOSDAQ
₩2,875+2.31%
2026-09-04 close

iNtRON Biotechnology last closed at ₩2,875 (+2.31%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

B
Overall: 건강관리 131/291 · top 45%
Factor composite · relative position in sector

PER — · PBR 1.16 — own-history percentile 9/100 · 100/100

Open self-history band
PER9/100
PBR100/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart2024: 100원20242025: 100원100원2025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
D
Yield
B+
Safety
F
Reference indicatorView observed cut rates

Paid 2 consecutive years · Raised 0 consecutive years · Yield 3.48% (based on 2025 payment of 100원)

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 38.88
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
38.88
Beneish M-Score
-3.44

No statistical flag

Sloan accrual
-2.84%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

3/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score3/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityWarning

OCF/매출 3기 연속 하락. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업외손익 급변 (영업이익 대비 63% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 253 of 287, share 0%.

253 / 2870%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6인트론바이오0%

Concentration

DistributedCR3 16.6%
HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
13.9
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-81.6%
Interest coverage
-223.7x
Return on equity (ROE)
-3.1%

Operating margin −5pp

Operating loss
Interest coverageBase -223.7x adverse case -237.4x
Return on equity (ROE)Base -3.1% adverse case -6.7%

Revenue −15%

Interest coverage risk
Interest coverageBase -223.7x adverse case -190.2x
Return on equity (ROE)Base -3.1% adverse case -5.3%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -223.7x adverse case -69.4x
Return on equity (ROE)Base -3.1% adverse case -6.3%

Interest coverage limit

Already below the limit by 82pp

Interest coverage limit at an operating margin of 0.4%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-11

Suppliers disclosed by the company in its 2026-03-11 annual report.

Purchase amount

KRW 100m
  1. Protease
    KRW 1,108T
  2. Inhibitor
    KRW 1,000T
  3. Nucleotides
    KRW 1,000T
  4. Rnase
    KRW 1,000T

Suppliers without disclosed amount

DNAChaotropicSalt

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 윤성준18.82%2026-07-21 · 증감 0.00%p

Connections

AI-extracted related companies · for reference

Same theme
미국 질병통제예방센터노보노디스크
🔗 See in the full market map →

Recent filings

iNtRON Biotechnology's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About iNtRON Biotechnology
What technical signals does iNtRON Biotechnology (048530) have?
iNtRON Biotechnology current technical signals: no active technical signal.
Is iNtRON Biotechnology a cup-and-handle pattern?
No. iNtRON Biotechnology has no valid cup-and-handle signal right now.
What are iNtRON Biotechnology's financials and valuation?
iNtRON Biotechnology's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy